Wockhardt Ltd. has received final approval from the United States Food & Drug Administration for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy. Lamotrigine is the generic name for the brand Lamictal XR, marketed in the United States by Glaxo SmithKline. Wockhardt is launching the product immediately and will be amongst the earliest generic version of this product in the market.